- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- Nipro PharmaPackaging Ural LLC
Nipro PharmaPackaging Ural LLC
Nipro PharmaPackaging Ural LLC is a 100% subsidiary of NIPRO (Japan).
The company is engaged in manufacture of primary glass packaging for pharmaceutical industry.
Ampoules, vials, cartridges are made exclusively of a glass tube of the 1st hydrolytic class Type I, in accordance with European, American, Japanese pharmacopoeias, of the following brands: NSV51 (manufacturer – Nipro PharmaPackaging), Fiolax (manufacturer Schott), FS5.0 (manufacturer Four Stars, China) and JUNHENG (manufacturer – Triumph Junheng, China).
The range of products manufactured by the company includes:
• Ampoules: 1 to 25 ml, forms B, C, D, E; made of clear and amber glass, with open point cut or cut ring, in accordance with ISO 9187 It is possible to apply marker rings to the ampoules.
• Vials: 1 to 30 ml, made of clear and amber glass, with a crimp neck, in accordance with ISO 8362
• Cartridges with a nominal capacity of 1.5; 1.8; 3 ml; made of clear glass in accordance with ISO 13926
Technological lines are equipped with options for printing on products, which allows you to apply a company logo or other information, for additional protection of medicines against counterfeiting.
In addition to standard products, the company is capable to manufacture products in accordance with individual customer drawings.
Total production is about 260 million items per year. The plant is equipped with the latest equipment: European made ampoule and vial lines by OCMI (Italy), a cartridge line of own production by NIPRO (France). All technological lines are equipped with automated quality control systems VIMEC (Netherlands), which allows rejecting products for geometric, cosmetic and mechanical defects.
The company implemented a quality management system certified in accordance with ISO 9001:2015, ISO 15378 (Special requirements for ISO 9001:2008 implementation, taking into account Good Manufacturing Practice GMP).
